Prescription software for preventing heart disease
Silent global epidemic
Problem worth solving
Heart disease is the world’s #1 killer with 18 million deaths each year. According to WHO, 80% of these deaths could be prevented - that’s 14,5 million lives saved annually with the right tools.
An early indication for heart disease is a condition called metabolic syndrome - a cluster of 3+ cardiovascular risk factors. Global prevalence of metabolic syndrome is growing fast, affecting nearly 25% of the world’s adult population - that’s over 1,3 billion people worldwide.
Since most of these risk factors don’t have visible symptoms, 91% of metabolic syndrome cases are undiagnosed and untreated, greatly increasing the likelihood of developing heart disease. This is a huge economic burden on healthcare systems and society globally.
Digital therapeutics for metabolic syndrome
We are working with leading research institutions to build the world’s first AI-driven DTx platform for metabolic syndrome that improves patient outcomes, saves cost and scales like software.
The €1 million R&D project brings together world-class scientists, engineers and medical experts to develop a Software as a Medical Device (SaMD) platform for preventing, monitoring and treating metabolic syndrome related disorders.
The platform features a metabolic risk prediction model and unique behavioral activation technology that combines clinical guidelines, behavioral science and AI to create highly personalised intervention programs.
What are digital therapeutics?
A new class of medicine
Digital therapeutics (DTx) are clinically proven software applications prescribed by physicians to prevent or treat specific diseases.
Digital therapeutic applications go through clinical trials and regulatory review, similar to a traditional drug or medical device, in order to validate their safety and efficacy.
The difference between a Digital Therapeutic and other health apps is similar to that between a supplement like Vitamin C, and a prescription drug from a pharmacy.
This project is funded by European Regional Development Fund and Enterprise Estonia